: This is a commentary on Agnes Mattsson. et al., Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy
Mondello, Patrizia
Primo
;
2020-01-01
Abstract
: This is a commentary on Agnes Mattsson. et al., Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
